✦ LIBER ✦

S1045 Endoscopic Mucosal Improvement in Patients With Active Crohn's Disease Treated With Certolizumab Pegol: Week 10 and 54 Results of the Music Trial

✍ Scribed by Jean-Frederic Colombel; Marc Lemann; Yoram Bouhnik; Olivier Dewit; Jean-Louis Dupas; Michael R. Mross; Geert R. D'Haens; Krassimir Mitchev; Severine Vermeire; Hedia Brixi-Benmansour; Tom G. Moreels; Xavier Hebuterne

Book ID: 119431610
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 91 KB
Volume: 138
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(10)60761-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S1065 Predictors of Endoscopic Response

S1065 Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data

✍ Jean-Frederic Colombel; Marc Lemann; Matthieu Allez; Krassimir Mitchev; Corinne 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 100 KB

PGI4 Health-Related Quality of Life Impr

✍ Hébuterne, X.; †Lémann, M.; Coteur, G.; Ernault, E.; Colombel, J.F. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Randomised clinical trial: improvement i

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

✍ B. G. Feagan; W. J. Sandborn; D. C. Wolf; G. Coteur; O. Purcaru; Y. Brabant; P. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

494 Efficacy and Safety of Certolizumab

494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study

✍ Severine Vermeire; Maria T. Abreu; Geert D'Haens; Jean-Frédéric Colombel; Krassi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 104 KB